New 5-year plan to combat antimicrobial resistance

A new plan to tackle antimicrobial resistance, a global issue that makes infections difficult or impossible to treat, has been launched by the government.

The national action plan will commit the UK to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals, strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments.

It commits to continue to innovate through initiatives such as indicating that that the world-first ‘subscription model’ for antimicrobials, which was launched in 2019 as a pilot, could be expanded. This will see more companies paid a fixed annual fee for antimicrobials based primarily on their value to the NHS, as opposed to the volumes used.

The plan will build on progress towards the UK’s 20-year vision for antimicrobial resistance, which will see AMR contained, controlled and mitigated - protecting public health by increasing the risk of disease spread, severe illness, disability and death. 

Health Minister Maria Caulfield said: "Almost 8,000 people in the UK die from drug-resistant infections every year. If this continues to spread, common infections and injuries that were once easily treatable become harder, and in some cases impossible, to treat. 

"Our 5-year action plan outlines our commitment to leading the way in tackling AMR, including through expanding our world-first subscription model to accelerate research into new treatments."

The new plan has 9 strategic outcomes organised under 4 themes:

  1. Reducing the need for, and unintentional exposure to, antimicrobials - this includes activity to prevent infections arising in the first place (through good infection prevention and control, including vaccination), to monitor the emergence and spread of AMR through strengthened surveillance, and to minimise release of antimicrobials and resistance into the environment.
  2. Optimising the use of antimicrobials - through ensuring antimicrobials are only used when needed in humans, animals and the environment.
  3. Investing in innovation, supply and access - by supporting and incentivising the development of new vaccines, diagnostics and therapeutics (including alternatives to antimicrobials), making them accessible to those who need them, and ensuring our work on AMR is informed by cutting edge research.
  4. Being a good global partner - maintaining the UK’s role as an international leader on AMR and supporting low and middle income countries to respond to the threat of AMR through research, good supply chains and access to antibiotics.

To view the full plan, visit: https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2024-to-2029

Latest Issues

CSC Autumn Study Day 2024

Crowne Plaza Birmingham NEC
14th October 2024

BAUN 2024 Annual Conference

ACC, Liverpool
3rd - 5th November 2024

The AfPP Roadshow - Belfast

ICC Belfast
9th November 2024

IDSc Annual Conference 2024

Hilton Birmingham Metropole Hotel
26th - 27th November 2024

IV Forum 2024

Birmingham Conference & Events Centre (BCEC)
Wednesday 4th December 2024

The AfPP Roadshow - Leeds

TBA, Leeds
7th December 2024